IMNR - Immune Response Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert Knight who wrote (664)	6/30/1998 12:46:00 PM
From: Jonas Grumby	of 1510

This excerpt says it ALL..read it twice..she is a beauty... ''We made the decision to aggressively pursue this opportunity with Immune Response after a comprehensive review of clinical data of REMUNE from a number of studies, which convinced us of the unique potential of this product to make a powerful contribution to the treatment of HIV infection and AIDS,'' said Peter Johnson, Agouron's president and chief executive officer. ''Prominent among these data were encouraging preliminary results from a study of REMUNE taken in combination with highly active antiretroviral drugs -- results that will be presented at the upcoming 12th World AIDS Conference in Geneva later this month. hiccup -- results that will be presented at the upcoming 12th World AIDS Conference in Geneva later this month. Jonas

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next